INTRODUCTION

• Brodalumab is a human anti–interleukin-17 receptor A monoclonal antibody that is efficacious in treating moderate-to-severe psoriasis

• Maintenance of skin clearance among patients receiving brodalumab 210 mg subcutaneously every 2 weeks (Q2W) stratified by categories of psoriasis area and severity index (PASI) response at 12 weeks was previously assessed in two phase 3 studies (AMAGINE-2/-3) of adults with moderate-to-severe plaque psoriasis

OBJECTIVE

• To evaluate skin clearance response with brodalumab 210 mg Q2W through week 52 in the phase 3, double-blind, randomized, placebo-controlled AMAGINE-1 trial

METHODS

• Patients in AMAGINE-I were initially randomized to brodalumab 210 mg Q2W or placebo for 12 weeks

• After 12 weeks, those receiving brodalumab 210 mg Q2W who achieved static physician's global assessment score of 0 or 1 (sPGA 0/1) were re-randomized to brodalumab 210 mg Q2W or placebo

• Beginning at week 16, patients re-randomized to placebo who had return of disease, defined as sPGA ≥3, qualified for retreatment with their induction dose of brodalumab

• 128 patients from AMAGINE-1 who received continuous brodalumab 210 mg Q2W through week 52 were included in this post hoc analysis comprising:
  – 83 patients who were re-randomized to brodalumab 210 mg Q2W
  – 45 non-re-randomized patients who received brodalumab 210 mg Q2W after inadequate sPGA response

• Skin clearance was monitored by categories of PASI response using nonresponder imputation

RESULTS

Week 12 PASI Responses

• At week 12, among 128 patients who received continuous brodalumab 210 mg Q2W, 63% achieved PASI 90% improvement (PASI 90) or greater (37% achieved PASI 100 and 26% achieved PASI 90 to <100; Table 1)

Table 1. PASI Response at Week 12 in AMAGINE-I

<table>
<thead>
<tr>
<th>Response at week 12, n (%)</th>
<th>Continuous brodalumab 210 mg Q2W (N=128)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PASI 100</td>
<td>47 (37)</td>
</tr>
<tr>
<td>PASI 90 to &lt;100</td>
<td>33 (26)</td>
</tr>
<tr>
<td>PASI 75 to &lt;90</td>
<td>21 (16)</td>
</tr>
<tr>
<td>PASI 50 to &lt;75</td>
<td>11 (9)</td>
</tr>
<tr>
<td>PASI &lt;50</td>
<td>16 (13)</td>
</tr>
</tbody>
</table>

PASI, psoriasis area and severity index; Q2W, every 2 weeks.

PASI Responses at Weeks 16, 28, and 52

• Among patients achieving PASI 100 at week 12, >75% maintained PASI 100 at weeks 16 and 28
  – 81% maintained PASI 100 at week 16
  – 77% maintained PASI 100 at week 28

• Among patients achieving PASI 100 at week 12, 79% maintained PASI 100 through week 52

• Notably, most patients (64%) who achieved PASI 90 to <100 at week 12 either improved to PASI 100 (49%) or maintained the same level of clearance (15%; Figure 1) at week 52

CONCLUSIONS

• These data demonstrate maintenance and continued improvement of skin clearance through week 52 with brodalumab

Acknowledgments: This study was sponsored by Ortho Dermatologics. Medical writing support was provided by MedThrive ScinCom and funded by Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US, LLC.